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Edited by Veli-Pekka LehtoAbstract Unstimulated human ﬁbrosarcoma cells (HT1080)
constitutively secrete matrix metalloproteinase 2 (MMP 2) as a
proenzyme requiring proteolytic cleavage by membrane type-1
MMP (MT1 MMP) for activation. Physiological and pharma-
cological stimuli induce clustering of MT1 MMP/tissue inhibitor
of MMP 2 ‘‘receptors’’, promoting binding and activation of
MMP 2. We now report that cholesterol depleted HT1080 cells
accumulated MT1MMP on the cell surface and activated MMP
2. A speciﬁc inhibitor of mitogen activated protein kinase kinase
1/2 inhibited both MMP 2 activation and extracellular signal-
related kinase phosphorylation induced by cholesterol depletion.
Our data indicate that the cholesterol content of unstimulated
cells is critical for secretion of MMP 2 as an inactive zymogen
and control of pericellular proteolysis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Membrane type-1 matrix metalloproteinase (MT1 MMP),
the ﬁrst of the cell surface-associated subset of the MMP
family, undergoes constitutive endocytosis and recycling to the
plasma membrane [1]. Invading tumour cells localise MT1
MMP in specialised structures termed invadopodia [2], where
rapid renewal is required as it is subject to constant autocat-
alytic degradation [3,4]. The trimolecular activation complex
between MT1 MMP, tissue inhibitor of metalloproteinases 2
(TIMP 2) and pro-MMP 2, is well-documented [5–7]. In ad-
dition, MT1 MMP eﬃciently degrades extracellular matrix
(ECM) components, processes bioactive cell surface molecules
and regulates migration, invasion and proliferation of cancer
cells [8–10]. These observations have signiﬁcant implications
for tumour cell biology, as increased levels of MT1 MMP and
active MMP 2 correlate well with a poor prognosis for cancer
patients [11]. Understanding the traﬃcking pathways involved
in the secretion of MT1 MMP to the plasma membrane and its* Corresponding author. Fax: +44-1223-762323.
E-mail address: gm290@cam.ac.uk (G. Murphy).
Abbreviations: MMP, matrix metalloproteinase; MT1 MMP, mem-
brane type-1 MMP; MbCD, methyl-b-cyclodextrin; TIMP, tissue
inhibitor of MMP; ERK, extracellular signal-related kinase; MEK,
mitogen activated protein kinase kinase
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doi:10.1016/j.febslet.2004.04.040fate thereafter will be important in the development of po-
tential cancer therapies.
Both clathrin coated pit and caveolae mediated pathways
have been implicated in the endocytosis and recycling of MT1
MMP. The enzyme, together with MMP 2, co-localises with
caveolin-1 [12,13] and is present in isolated low density,
caveolin-1 positive membrane fractions [1,12–14]. Cellular
cholesterol is a fundamental requirement for the formation of
the characteristic ﬂask shaped plasma membrane invagin-
ations, known as caveolae, whose major structural proteins are
the caveolins. Cholesterol depleting drugs, e.g., methyl-b-
cyclodextrin (MbCD), cause loss of caveolae structure so that
they become ﬂattened and more accessible to the ECM. Under
these conditions they can no longer function as intracellular
traﬃcking vesicles and participate in endocytosis. Caveolae are
a morphologically distinct subset of a much larger group of
cholesterol enriched membrane lipid domains, collectively
known as lipid rafts (reviewed by Lai [15]). All of these do-
mains are participants in signal transduction and membrane
and protein sorting, thus multiple additional eﬀects of cellular
cholesterol depletion are documented including activation and
delocalisation of signalling molecules and growth factor re-
ceptors [16–18] and alterations to the actin cytoskeleton.
Inhibition of endocytosis with vacuolar H+ATP-ase in-
hibitors, folimycin or baﬁlomycin A, allows an accumulation
of MT1MMP at the cell surface and concomitant activation of
MMP 2 [19,20]. We now demonstrate that perturbing endo-
cytosis by means of cholesterol depletion results in MMP 2
activation. We show that this is MT1 MMP dependent and
examine the changes in the cellular localisation and status of
MT1 MMP protein. We also investigate intracellular signal
transduction pathways involved in this induced activation of
MMP 2 and provide evidence for a requirement for extracel-
lular signal-related kinase (ERK) activation.2. Materials and methods
2.1. Antibodies
Anti-human MT1 MMP sheep polyclonal antibody was as described
[21]. Secondary antibodies conjugated to horseradish peroxidase and
anti-biotin monoclonal antibody were all from Jackson Immunore-
search, Stratech Scientiﬁc Ltd,UK.Monoclonal antibodies to phospho-
ERK and ERK 2 were from Santa Cruz, Insight biotechnology, UK.
2.2. Cell culture
Human ﬁbrosarcoma cell line, HT1080 cells were seeded at 105 cells/
well in DMEM with 10% FCS and incubated at 37 C, 5% CO2 for 24blished by Elsevier B.V. All rights reserved.
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cubated at 37 C overnight before cholesterol depletion experiments.
2.3. Cholesterol depletion
Washed cells were incubated at 37 C, 5% CO2 in DMEM, 50 mM
HEPES, pH 7.2, and 0.1% BSA, with varying concentrations of
MbCD (Sigma, UK) for 30 min, then washed and incubated for 1 or 2
h in DMEM. Cell supernatants were concentrated (1 h samples) before
analysis by gelatin zymography. Cell lysates were prepared as de-
scribed [3] and Western blotted for MT1 MMP.
2.4. Gelatin zymography
Samples were electrophoresed on SDS–7% PAGE containing 1 mg/
ml gelatin, washed in Triton X-100, incubated overnight at 37 C and
stained with Coomassie brilliant blue.
2.5. Cholesterol repletion
For cholesterol repletion experiments, cholesterol/(MbCD) com-
plexes were prepared as described [22]. For use the complexes were
diluted to 0.2 mM cholesterol using DMEM/HEPES pH 7.2, and 0.1%
BSA. After an initial incubation with MbCD as before, the cells were
incubated for 10, 20, 30 or 40 min in DMEM/HEPES, pH 7.2, 0.1%
BSA with or without cholesterol/MbCD complexes. After each time
point, the cells were washed and incubated for a further 2 h in DMEM.
Cell supernatants were harvested for gelatin zymography as before.
2.6. TIMP inhibition
TIMP 1 [23] or TIMP 2 [24] (100 nM as determined by active-site
titration [24]) was added during the ﬁnal 1-h incubation as described
above.
2.7. Inhibition of signalling pathways
SB20358 (25 lM), LY294002 (25 lM), UO126 (10 lM), all from
Calbiochem, Merck Biosciences, UK, PD 98059 (20 lM, Qbiogene-
Alexis Ltd, UK) or Staurosporine (100 nM, Sigma, UK) were added to
cultures during 30 min pre-incubation, 30 min incubation with or
without MbCD and during 2 h incubation in DMEM.
2.8. Biotinylation of cell surface proteins
HT1080 cells were seeded into 6-well plates (1/20 80% conﬂuent T75
ﬂask/well) and incubated overnight at 37 C in DMEM with 10% FCS.
Cells were serum depleted for 18 h and then washed and incubated for
30 min with or without MbCD. Biotinylation of cell surface proteins
was performed, either immediately afterwards or after a further 60 min
incubation in DMEM, essentially as described [1] using 0.5 mg/ml EZ-
link non-permeable sulfo-NHS-LC-biotin (Perbio Science, UK) for 20
min at room temperature.
2.9. Immunoprecipitation
Lysates were pre-cleared with protein G–Sepharose overnight at
4 C and biotinylated proteins were immunoprecipitated with anti-
biotin as described [1]. Bound antibody/antigen complexes were wa-
shed and eluted from the beads with reducing Laemmli sample buﬀer.
2.10. Western blot analysis
Immunoprecipitates were separated on SDS–10% PAGE and pro-
teins transferred overnight onto nitrocellulose membranes and probed
for biotinylated and unbound MT1 MMP with the polyclonal anti-
body (1 lg/ml). Lysates were Western blotted as above and probed for
MT1 MMP or for phosphorylated ERK or total ERK 2.Fig. 1. MbCD induces MMP 2 activation in HT1080 cells. Serum
starved HT1080 cells were incubated for 30 min at 37 C with or
without MbCD (0, 2.5, 5, 10 mg/ml). Cells were incubated further for 1
h in DMEM only and concentrated cell supernatants were analysed by
gelatin zymography for MMP 2 activation. For comparison cells were
incubated with 0.5 lg/ml folimycin (F) or 20 ng/ml PMA (P) (left
panel). MbCD (0, 2.5, 5, 10 mg/ml) treated cell lysates from a sepa-
rate experiment were analysed by Western blot for MT1 MMP (right
panel).3. Results and discussion
Despite intense investigation into the role ofMT1MMP as an
activator ofMMP 2 and latterly as a regulator of the pericellular
environment and tumour cell proliferation, little is understood
about the mechanisms underlying its transport to the plasma
membrane and sites of function. In this reportwe describe for the
ﬁrst time how, in unstimulated HT1080 cells, its MMP 2 acti-
vating capacity is controlledby the cholesterol content of the cell.3.1. MbCD dose dependently induces activation of MMP 2
Depletion of cholesterol with MbCD for 30 min induced
dose dependent MMP 2 activation. Pro, intermediate and ac-
tive MMP 2 were detected in media from treated cells com-
pared to only the pro form in untreated cells (Fig. 1, upper
panel). Cholesterol depletion was more eﬀective than phorbol
ester stimulation or folimycin at this short time point and an
accumulation of the intermediate form, generated by MT1
MMP cleavage [6] was apparent with 10 mg/ml MbCD, sug-
gesting increased availability of MT1 MMP. Increased inactive
(43–45 kDa) MT1 MMP was detected in lysates from cells
treated with 2.5 or 5 mg/ml MbCD, compared to untreated
cells (Fig. 1, lower panel). These products of MT1 MMP au-
tocatalytic degradation are often closely correlated with levels
of MMP 2 activation [3,4,25]. Higher concentrations of MbCD
(10 mg/ml) caused some loss of cells and we therefore chose a
concentration of 5 mg/ml for subsequent experiments. Incu-
bation with MbCD, PMA or folimycin for 30 min at the
concentrations shown did not aﬀect cell viability as assessed by
trypan blue exclusion (data not shown). In addition, two other
drugs, ﬁlipin and nystatin, induced similar MMP 2 activation
(data not shown), indicating that the eﬀect was due to the
depletion of cholesterol and not speciﬁc to MbCD.
3.2. MbCD induced MMP 2 activation is MT1 MMP mediated
In order to conﬁrm that MbCD induced MMP 2 activation
was MT1 MMP mediated, we investigated its inhibition by
TIMPs 1 and 2. TIMP 1 inhibited only the ﬁnal autocatalytic
step in accordance with its negligible inhibitory capacity versus
MT1 MMP [26]. In contrast, TIMP 2 completely inhibited any
processing of MMP 2 (Fig. 2, upper panel). Additionally
TIMP 2, but not TIMP 1, abolished proteolytic cleavage of
active MT1 MMP resulting in increased 60 kDa MT1 MMP
(Fig. 2, lower panel) and conﬁrming that the 43–45 kDa forms
are products of MT1 MMP autocatalysis. Thus, the TIMP
inhibition proﬁle identiﬁed MMP 2 activation induced by
cholesterol depletion as MT1 MMP dependent.
3.3. Cholesterol replenishment reverses MMP 2 activation
We next investigated whether replenishing cholesterol in
cholesterol-depleted cells could reverse MMP 2 activation.
Fig. 4. Cholesterol depletion increases the amount of MT1 MMP on
the cell surface. HT1080 cells were incubated for 30 min at 37 C with
or without MbCD or with folimycin, then further incubated for 60 min
in DMEM. Surface proteins were biotinylated as described and im-
munoprecipitated with an anti-biotin antibody. The immunoprecipi-
tates and unbound fractions were analysed by Western blotting for
MT1 MMP. Upper panel, biotinylated MT1 MMP (cell surface) in the
bound fraction; lower panel, non-biotinylated MT1 MMP (intracel-
lular) in the unbound fraction. Bar charts represent densitometric
analysis of the blots; solid bars, 60 kDa bands, hatched bars, 43–45
kDa bands.
Fig. 2. TIMP 2 inhibits MMP 2 activation induced by MbCD. HT1080
cells were incubated for 30 min at 37 C with 5 mg/ml MbCD. DMEM
with or without TIMPs (100 nM) was added and the cells incubated
further for 1 h after removal of MbCD. Concentrated cell supernatants
were analysed by gelatin zymography (left panel). Cell lysates were
analysed by Western blotting for MT1 MMP (right panel).
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pletion with cholesterol/MbCD complexes that have the ability
to restore the cholesterol content of the plasma membrane
[16,27]. At least 30 min incubation with the complexes was
required to reverse MMP 2 activation (Fig. 3). Neither MbCD
nor cholesterol/MbCD complexes had any eﬀect on MMP 9,
which is constitutively secreted in the pro-form (92 kDa) by
these cells (Fig. 3).
3.4. MbCD increases the amount of MT1 MMP on the cell
surface
A major eﬀect of cholesterol depletion in cells is disruption
of the structural integrity of caveolae resulting in inhibition of
endocytosis. We examined cell surface expression of MT1
MMP after incubation with MbCD or folimycin by biotiny-
lation of cell surface proteins. Both treatments resulted in in-
creased, biotinylated 60 and 43–45 kDa MT1 MMP at the cell
surface, compared to untreated cells (Fig. 4, top panel). These
diﬀerences in levels of cell surface MT1 MMP could not be
detected immediately after MbCD treatment but only after the
total 90 min experimental period. In agreement with previousFig. 3. Cholesterol repletion reverses MMP 2 activation induced by
MbCD. HT1080 cells were incubated for 30 min at 37 C with or
without 5 mg/ml MbCD followed by incubation with cholesterol/
MbCD complexes or medium only as described for the times shown.
Cells were washed after each time point and further incubated for 2 h
in DMEM. Cell supernatants were analysed by gelatin zymography.reports using folimycin [19,20], we conclude that this was due
to inhibition of the constitutive turnover of MT1 MMP by
endocytosis resulting in an accumulation of active MT1 MMP.
Cholesterol depletion is used to distinguish between caveolae-
dependent and other endocytic pathways [28], but MbCD can
inhibit both caveolae and clathrin-dependent endocytosis [29].
Recently, we reported that MT1 MMP is endocytosed via each
of these pathways [1] but it is unclear whether both the active
form and its degraded forms are internalised through the same,
both or individual pathways. Separation techniques for cave-
olae enriched fractions, in which MT1 MMP is detected, iso-
late low-density fractions that include caveolin negative lipid
rafts [30]. Alternative protocols are required to conﬁrm that
the majority of MT1 MMP is associated with caveolae and it is
likely that the association varies between cell types and be-
tween diﬀerent forms of MT1 MMP.
Inhibition of endocytosis is however unlikely to account for
the total eﬀects of cholesterol depletion on MMP 2 activation.
EGF receptors associate with mainly non-caveolar lipid rafts
such that EGF binding is inhibited [31]. It may be that a
proportion of MT1 MMP is associated with lipid rafts in a
manner that precludes its activation or alternatively that does
not allow TIMP 2 binding and thus prevents formation of the
MMP 2-activation complex. Recent work, published whilst
this manuscript was in preparation [32], suggests that lipid raft
association has no eﬀect on MT1 MMP mediated activation of
MMP 2. Cytoplasmic domain deleted MT1 MMP but not wild
type MT1 MMP, expressed in MCF 7 breast carcinoma cells,
was present in caveolin enriched membrane domains. Despite
this both enzymes activated MMP 2. Others agree with our
own observations, i.e., that endogenous MT1 MMP in
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fractions prepared from non-detergent cell extracts [1,14]. Our
data here demonstrate induced MMP 2 activation when cho-
lesterol is depleted, a process known to disrupt caveolae. It is
possible, therefore, that in HT1080 cells, MT1 MMP or the
other components of the trimolecular activation complex may
have an association with caveolin-1 resulting in negative reg-
ulation as has been described for EMMPRIN/CD147 [33].
Caveolae endocytosis is reported to be the major traﬃcking
pathway for MT1 MMP in human endothelial cells, however,
in these cells, no association between caveolin 1 and MT1
MMP was demonstrated [13].
3.5. MMP 2 activation induced by cholesterol depletion requires
the ERK signalling pathway
Depletion of cholesterol is reported to modulate signal
transduction pathways in a variety of cell types [16–18,34–36].
We assessed the eﬀects of inhibitors of a number of signal
transduction pathways on MMP 2 activation induced by
MbCD. Activation was consistently inhibited by U0126, an
inhibitor of mitogen activated protein kinase kinase (MEK1/2)
activation (Fig. 5A, lanes 7 and 8), but not by an inhibitor of
stress activated protein kinase 2a (SAPK 2a/p38 MAPK)
(SB203580) (Fig. 5A, lanes 11 and 12). Surprisingly, cells ex-
posed to SB203580 alone responded with an induction of
MMP 2 activation (Fig. 5A, lanes 9 and 10), indicative of an
alternative processing mechanism, however SB203580 did notFig. 5. MMP 2 activation induced by cholesterol depletion requires the
ERK signalling pathway. (A) Serum depleted HT1080 cells were pre-
incubated for 30 min at 37 C with vehicle control, DMSO, or inhib-
itors as shown. Media were removed and replaced with or without 5
mg/ml Mb CD and inhibitors for a further 30 min at 37 C. Cells were
incubated for a further 2 h at 37 C in DMEM alone or with inhibitors.
Cell supernatants were analysed by gelatin zymography (upper panel)
and cell lysates by Western blotting for MT1 MMP (lower panel). (B)
Serum depleted HT1080 cells were pre-incubated for 30 min at 37 C
with or without 100 nM staurosporine as shown. Media were removed
and replaced with 20 ng/ml PMA or 5 mg/ml MbCD plus or minus
staurosporine as shown, then incubated at 37 C for a further 30 min.
Finally, cells were washed and incubated with DMEM with or without
inhibitor for 2 h at 37 C. Cell supernatants were analysed by gelatin
zymography for MMP 2 activation.signiﬁcantly increase activation induced by MbCD. Another
inhibitor of MEK activation (PD 98059) also inhibited MMP 2
activation induced by MbCD but was less eﬀective than
UO126 (data not shown). Both inhibitors of MEK activation
led to a reduction of 43–45 kDa MT1 MMP (Fig. 5A, lower
panel) but in the presence of SB203580, the amount of 43–45
kDa MT1 MMP was comparable to that seen with cyclodex-
trin alone (Fig. 5A, lower panel).
3.6. Cholesterol depletion in HT1080 cells induces ERK
activation
ERK1/2 is the downstream target for active MEK1/2 and so
it was of interest to determine whether cholesterol depletion
has an eﬀect on the activity of ERK in HT1080 cells. MbCD
induced ERK activation (Fig. 6, lane 5), which was totally
abolished by the presence of U0126 and severely reduced by
PD98059 (Fig. 6, lanes 6 and 7). Interestingly, SB203580 in-
duced ERK activation even in cells incubated without cyclo-
dextrin (Fig. 6, lane 4), thus MMP 2 activation induced by
SB203580 alone (Fig. 5A, lanes 9 and 10) is coincident with
ERK phosphorylation, but we have yet to demonstrate a
causal link between the two.
Caveolin binding motifs are found within the catalytically
active enzyme domain of many signalling molecules, suggest-
ing that caveolin 1 is a general inhibitor of kinases. In support
of this, activation of the ERK signalling cascade in response to
cholesterol depletion and caveolin downregulation is widely
reported [37]. We found that the ERK pathway was activated
in HT1080 cells in response to MbCD treatment, coincident
with MMP 2 activation, and that a speciﬁc inhibitor of MEK-1
inhibited the activation of both. Activation of the ERK sig-
nalling cascade has previously been observed with respect to
MMP 2 activation in addition to MT1 MMP expression and
cell migration and invasion [38–42]. A new study [43] supports
these ﬁndings, since MMP 2 activation induced by type 1
collagen was inhibited with PD 98059 and induced by the
overexpression of a constitutively active form of MEK-1. The
formation of homophilic MT1 MMP complexes at the cell
surface is required for MMP 2 activation [44,45], thus oligo-
merisation of MT1 MMP in response to cholesterol depletion
may be suﬃcient to initiate signal transduction leading to ac-
tivation of MMP 2. Alternatively, increased TIMP 2 binding
to MT1 MMP might initiate an ERK signalling cascade cul-
minating in MMP 2 activation. More work is needed to sub-
stantiate these hypotheses.Fig. 6. Cholesterol depletion induces ERK activation. HT1080 cells
were pre-incubated for 30 min at 37 C with signalling inhibitors as
shown, then incubated with or without 5 mg/ml MbCD for 30 min at
37 C in the presence of the inhibitors. Cell lysates were prepared
immediately after cholesterol depletion and analysed by Western
blotting for phosphorylated ERK. The blots were then reprobed for
total ERK 2.
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pathways are associated with lipid rafts including protein ki-
nase C (PKC) isoforms and phosphatidylinositol 3-kinase (PI
3K). Cholesterol depletion can also modulate the activity of
these pathways with resulting eﬀects on gene transcription [36].
We therefore investigated whether they have a role in MMP 2
activation induced by cholesterol depletion. PKC mediated
signalling pathways appear not to be involved in MMP 2 ac-
tivation induced by cholesterol depletion in HT1080 cells
(Fig. 5B, right panel). However, staurosporine partially inhib-
ited PMA stimulated MMP 2 activation (Fig. 5B, left panel),
thus phorbol ester induced MMP 2 activation diﬀers from that
induced by cholesterol depletion. A diﬀerence in dependence on
PKC activation was also found with respect to the shedding of
the interleukin 6 receptor (IL6R) induced by cholesterol de-
pletion, compared to that induced by PMA [27]. Likewise, in-
hibitors of PI 3K,Wortmannin and LY294002, had no eﬀect on
MMP 2 activation induced by MbCD (data not shown).
Cholesterol depletion aﬀects cell morphology with altera-
tions to the actin cytoskeleton that have far-reaching eﬀects on
many intracellular processes, including endocytosis. Disrup-
tion of the actin cytoskeleton by both physiological and
pharmacological means is suﬃcient to induce MMP 2 activa-
tion [46]. We observed that MbCD induced HT1080 cell shape
change and that UO126 appeared to partially abrogate this
response (data not shown), indicating that ERK signalling to
cytoskeletal proteins was inhibited. Folimycin, on the other
hand, had no eﬀect on cell morphology but reproducibly and
eﬃciently induced activation of MMP 2. Undoubtedly, the
eﬀects of cholesterol depletion on the actin cytoskeleton con-
tributed to MMP 2 activation in our experiments. Concanav-
alin A and Cytochalasin D also induce MMP 2 activation in
cell culture accompanied by cell shape change. The former
additionally crosslinks molecules on the cell surface and in-
hibits internalisation of MT1 MMP but our attempts to de-
termine whether the Cytochalasin D eﬀect is mediated by
inhibition of MT1 MMP endocytosis have been inconsistent
(J. English, S. Atkinson, unpublished observations). It is likely
that the morphological changes in response to cholesterol de-
pletion have profound eﬀects on signal transduction, growth
factor receptor activation and membrane dynamics in addition
to the inhibition of MT1 MMP internalisation and recycling.
Overall, our data imply that in unstimulated human ﬁbro-
sarcoma cells the cholesterol content of cell membranes is
critical for the retention of MMP 2 in an inactive form. The
data reported here suggest that this is unlikely to be a direct
eﬀect of cholesterol per se but on a requirement for cholesterol
by the cell for the maintenance of endocytic pathways and a
dynamic actin cytoskeleton in addition to regulation of signal
transduction pathways. MMP 2 activation induced by choles-
terol depletion is thus largely due to disruption of continuous
constitutive recycling of MT1 MMP resulting in the protection
and accumulation of fully activeMT1MMP on the cell surface.
Our biotinylation experiments indicate that the accumulation
of MT1 MMP at the cell surface is not an immediate eﬀect of
cholesterol depletion, suggesting that the induced MMP 2 ac-
tivation is not simply the result of redistribution of functional
MT1 MMP from lipid raft localisation. Further work is re-
quired to establish whether cholesterol depletion releases MT1
MMP from negative regulation associated with lipid raft lo-
calisation without an immediate increase in surface MT1
MMP.Secondary signal transduction eﬀects via ERK are clearly
involved in this cholesterol depletion response, although the
precise mechanisms, which could include activation of nu-
merous growth factor receptors in addition to cytoskeletal
reorganisation, remain unresolved. However, the short-term
nature of these experiments is likely to rule out an eﬀect on
MT1 MMP transcription. Future studies will be directed to-
wards understanding the association of MT1 MMP and/or
MMP 2 and TIMP 2 with lipid enriched membrane microdo-
mains that this work has identiﬁed as an additional layer of
regulation of pericellular proteolysis.
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